CRUSH PAD: Real-world Outcomes Following Use of the Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions
- Study HIC#:2000031113
- Last Updated:12/22/2022
The primary goal of the study is to obtain effect size data on the use of Shockwave Intravascular Lithotripsy (IVL) technology in calcified common femoral lesions in patients with peripheral artery disease for a series of endpoints, including target lesion revascularization and health status, to enable future planning of comparative effectiveness research.
- Age18 years and older
For more information about this study, including how to volunteer, contact:
- Phone Number: 1-203-737-1168
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact firstname.lastname@example.org, or call +18779788343 for more information.
Trial Purpose and Description
The primary objective of this study is to evaluate the generic health status outcomes and efficacy and safety outcomes following use of the Shockwave Intravascular Lithotripsy (IVL) technology in calcified common femoral lesions in patients with PAD seen in routine clinical practice.
The main testable hypothesis is that the use of IVL is associated with a health status improvement that is equal or higher than the threshold of a minimally clinically important difference on the EQ5D. Preliminarily data will be derived for the primary endpoint target lesion revascularization to enable future planning of larger comparative effectiveness research.
Secondary objectives of the study are to document procedural success following the use of IVL in common femoral lesions, disease stage change, as well as disease-specific health status in the real-world.
- Subjects presenting with claudication or CLI by Rutherford Clinical Category 2, 3, 4, 5, or 6 of the target limbs
- Subject is a suitable candidate for angiography and endovascular intervention per the latest clinical guidelines
- Patient is scheduled to undergo treatment with Shockwave Intravascular Lithotripsy (IVL) technology followed by standard of care treatment with DCB, BMS, DES at the physician's discretion.
Angiographic Inclusion Criteria
- Target lesion that is located in a native, de novo common femoral artery
- Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visual estimate.
- Target lesion is ≥70% stenosis by investigator via visual estimate.
- Target lesion length is ≤50mm for lesions 70-99% stenosed. Target lesion can be all or part of the 50mm treated zone.
- Chronic total occlusion, lesion length is ≤50mm of the total ≤50 mm target lesion.
- Patient has open profunda femoris artery for the target leg, defined as no stenosis >50%.
- Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending > 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is <50mm in length.
- Subjects with any medical condition that would make him/her an inappropriate candidate for treatment with Shockwave Medical Peripheral Lithoplasty® System as per Instructions for Use (IFU) or investigator's opinion.
- Subject is already enrolled in other investigational (interventional) studies that would interfere with study endpoints.
- Cognitive impairment as documented in medical records
- Not speaking English or Spanish
- Currently a prisoner
- Pregnancy or nursing
- Estimated survival less than 12 months at the time of screening
- Prior history of CFA endarterectomy